LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

Home・Stock List・Mirati Therapeutics Inc

Search

Mirati Therapeutics Inc

Closed

Sector Healthcare

0

Overview

Share price change

24h

Current

Min

Max

Key metrics
By Trading Economics
Income	-162M
Sales	16M
EPS	-2.49
Profit margin	-987.22
EBITDA	-171M

Recommendations
By TipRanks
Recommendations	Neutral
12 Months Forecast	-0.05 downside

Market Stats
By TradingEconomics
Market Cap	-41M 4.1B
Previous open	0
Previous close	0

News Sentiment

By Acuity

11%

89%

11 / 365 Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

58.54 / 58.9 Support & Resistance

Mirati Therapeutics Inc Chart

Related News

9 Oct 2023, 14:15 UTC

Acquisitions, Mergers, Takeovers

Trending: Bristol Myers Squibb Buying Mirati Therapeutics

9 Oct 2023, 10:11 UTC

Major Market Movers

Acquisitions, Mergers, Takeovers

Mirati Shares Slip Premarket on Bristol Myers Takeover

6 Oct 2023, 06:41 UTC

Acquisitions, Mergers, Takeovers

Sanofi Considering Acquisition of Mirati Therapeutics, Bloomberg Reports

23 Jan 2024, 13:30 UTC

Acquisitions, Mergers, Takeovers

Bristol Myers Squibb Completes Acquisition of Mirati Therapeutics

9 Oct 2023, 15:25 UTC

Acquisitions, Mergers, Takeovers

Mirati Therapeutics Snags $5.8 Billion Takeover Deal, But Shares Fall On Lowball Bid -- IBD

9 Oct 2023, 13:56 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Bristol Still Has Flexibility After Mirati Deal -- Market Talk

9 Oct 2023, 13:52 UTC

Acquisitions, Mergers, Takeovers

Mirati Therapeutics Snags $5.8 Billion Takeover Deal, But Shares Fall On Lowball Bid -- IBD

9 Oct 2023, 13:40 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Guggenheim: Bristol-Mirati Deal Plugs Bristol's Holes -- Market Talk

9 Oct 2023, 11:18 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Bristol Hedges Mirati Bet With MRTX1719 CVRs -- Market Talk

9 Oct 2023, 09:27 UTC

Acquisitions, Mergers, Takeovers

Mirati Stock Falls as Bristol Myers to Buy Oncology Developer for Up to $5.8 Billion -- Barrons.com

8 Oct 2023, 22:12 UTC

Top News

Acquisitions, Mergers, Takeovers

Bristol Myers Squibb to Acquire Mirati Therapeutics in Deal Worth Up to $5.8 Billion -- WSJ

8 Oct 2023, 21:34 UTC

Acquisitions, Mergers, Takeovers

Bristol Myers Squibb to Finance Transaction With Cash and Debt

8 Oct 2023, 21:34 UTC

Acquisitions, Mergers, Takeovers

Bristol Myers Squibb: Transaction Will Be EPS Dilutive by $0.12/Share in First 12 Months

8 Oct 2023, 21:29 UTC

Acquisitions, Mergers, Takeovers

Bristol Myers Squibb: Non-Tradeable Rights Add $1 Bln of Value Opportunity

8 Oct 2023, 21:29 UTC

Acquisitions, Mergers, Takeovers

Bristol Myers Squibb: Mirati Board Unanimously Approves Transaction

8 Oct 2023, 21:28 UTC

Acquisitions, Mergers, Takeovers

Bristol Myers Squibb Will Also Pay One Contingent Value Right Per Share

8 Oct 2023, 21:27 UTC

Acquisitions, Mergers, Takeovers

Bristol Myers Squibb: Acquisition Values Mirati's Equity at $4.8 Bln

8 Oct 2023, 21:26 UTC

Acquisitions, Mergers, Takeovers

Bristol Myers Squibb to Acquire Mirati for $58/Share in Cash

8 Oct 2023, 21:26 UTC

Acquisitions, Mergers, Takeovers

Bristol-Myers Squibb: Transaction to Be Dilutive to Co's Non-GAAP EPS by About 35c/Shr in First 12 Mos After Transaction Closes >BMY

8 Oct 2023, 21:25 UTC

Acquisitions, Mergers, Takeovers

Bristol-Myers Squibb To Acquire Mirati for $58 Per Shr in Cash, for a Total Equity Value of $4.8B >BMY MRTX

Peer Comparison

Price change

Mirati Therapeutics Inc Forecast

Price Target

By TipRanks

-0.05% downside

12 Months Forecast

Average 58.67 USD -0.05%

High 59 USD

Low 58 USD

Based on 5 Wall Street analysts offering 12 month price targets forMirati Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

5 ratings

0

Buy

5

Hold

0

Sell

Based on 5 analysts giving stock ratings to Mirati Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

58.54 / 58.9Support & Resistance

Recent bearish events outweigh bullish events.

All events are bullish.

Bullish events outweigh bearish events.

Sentiment

By Acuity

11 / 365 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

EBITDA

Operating profit

$

About Mirati Therapeutics Inc

Mirati Therapeutics, Inc. is a clinical-stage oncology company. It is focused on developing therapeutics to address the genetic and immunological promoters of cancer. Its clinical programs consist of product candidates, including Adagrasib (MRTX849), MRTX1133, and Sitravatinib. MRTX849 is an oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. MRTX1133 is a small molecule-inhibitor of the KRASG12D mutation, designed to treat patients with unmet need. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that can stimulate the body’s immune response to fight cancer. MRTX849 is in Phase III and Phase I/II clinical trials and MRTX1133 is in preclinical development. Sitravatinib is in a Phase III clinical trial, and Phase I/II clinical trials. It also has additional preclinical discovery programs, which includes first-in-class and best-in-class product candidates designed to address mutations and tumors.

Other stocks from the sector

LLY

Eli Lilly and Co.

902.74

UNH

UnitedHealth Group Inc

596.8

NVO

Novo Nordisk A-S

131.05

JNJ

Johnson and Johnson

164.37

ABBV

AbbVie Inc

193.18